Advancing Education on Biosimilars Act of 2021
- Last Action
- 3/16/2021
Actions
- 2021-03-16Referred to the Subcommittee on Health.
- 2021-03-12Referred to the House Committee on Energy and Commerce.
- 2021-03-12Introduced in House
- 2021-03-12Introduced in House
CRS Summary
As of 2021-03-12 (00)
Advancing Education on Biosimilars Act of 2021
This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)
The FDA may also maintain and operate a website to provide educational materials about biological products.
Cosponsors (1)
- Scott Peters (D-CA)
Subjects
- Drug safety, medical device, and laboratory regulation
- Government information and archives
- Health personnel
- Licensing and registrations
- Medical education
- Prescription drugs
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.